Cancer

HSCI faculty member appointed the inaugural Regenerative Biology Endowed Chair at Boston Children’s Hospital

March 4, 2022

Fernando Camargo recognized for pioneering scientific contributions and outstanding leadership

Fernando Camargo, Ph.D., has been named as the inaugural Regenerative Biology Endowed Chair by the Boston Children’s Hospital (BCH) Department of Pediatrics, in recognition of his pioneering scientific contributions and outstanding leadership. Camargo is a professor in the Harvard Department of Stem Cell and Regenerative Biology (HSCRB) and Harvard Medical School (HMS)...

Read more about HSCI faculty member appointed the inaugural Regenerative Biology Endowed Chair at Boston Children’s Hospital

Call for Proposals: 2022 HSCI Cancer Program Pilot Grants

February 2, 2022

AWARD AMOUNT
Up to $100,000 for entire project period
Project period not to exceed 2 years

POSTED DATE
Wednesday, February 2, 2022

DEADLINE FOR APPLICATION
Friday, March 4,  2022

ANTICIPATED AWARD DATE
April  1, 2022

The Harvard Stem Cell Institute (HSCI) Cancer Program invites applications for pilot grants to be awarded for research in 2022. The intent is to provide resources for innovative projects dissecting stem/developmental programs in solid tumors that would help foster collaborations within the HSCI research community. This funding is for innovative, high-impact research projects. Multi-investigator, multi-institution proposals are encouraged; of specific interest to this funding cycle are proposals that dissect mechanisms that enable malignant stem cells to evade the immune system. Additionally, the applications should promote the Program mission: To identify critical genes and pathways that sufficiently distinguish cancer from normal stem cells and hence may serve as candidate targets for therapy.... Read more about Call for Proposals: 2022 HSCI Cancer Program Pilot Grants

A new study illuminates the therapy resistance of metastatic prostate cancer

November 15, 2021

Bone metastases are devastating developments of cancers that originate in other organs. In the case of metastatic prostate cancer, bone metastases represent an incurable, painful, and often deadly development, killing more than 30,000 American men every year. Unlike many other tumor types, metastatic prostate cancer responds poorly to immune-based therapies, but a new study published in Cancer Cell and originating in part from Harvard Stem Cell Institute (HSCI) labs, has uncovered a key mechanism for why such therapies fail to work, potentially leading the way to a breakthrough in the treatment of this devastating disease.... Read more about A new study illuminates the therapy resistance of metastatic prostate cancer

HSCI scientist receives award for lung cancer research

November 13, 2020

HSCI Executive Committee member Carla Kim is a recipient of the Lung Cancer Discovery Award from the American Lung Association. The award recognizes Kim’s innovative lung cancer research that has the potential to improve patient care and help save lives.

“As our nation faces COVID-19, we have not only witnessed its toll on our health, but we have also seen how air pollution,...

Read more about HSCI scientist receives award for lung cancer research

HSCI scientist awarded grant to develop gene therapy for HIV

September 7, 2020

HSCI co-director David Scadden is part of a multi-institutional, cross-disciplinary team that has been awarded a $14.6 million grant from the National Institutes of Health. The team is using gene and cell therapy approaches to develop a potential cure for HIV.

The researchers will combine gene editing against HIV with technologies for safer and more effective blood stem cell transplants. Such transplants, also known as bone marrow transplants, are currently used for severe blood cancers. They renew a patient’s immune system, which can be damaged by cancer therapies, by...

Read more about HSCI scientist awarded grant to develop gene therapy for HIV

HSCI scientist recognized for outstanding dermatology research

May 26, 2020

HSCI scientist Ya-Chieh Hsu, Ph.D. is the recipient of the 2020 LEO Foundation Award. The award recognizes extraordinary contributions to dermatology research that advance our understanding of skin diseases, and have the potential to pave the way for new and improved treatments.

Hsu is the Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology. She studies how communication among different cell...

Read more about HSCI scientist recognized for outstanding dermatology research

Pages